Prevention of posterior capsule opacification by intraoperative single-dose pharmacologic agents.
OBJECTIVE
To determine whether an intraoperative single dose of dexamethasone, diclofenac, ethylenediaminetetraacetic acid (EDTA), a combination of EDTA and RGD peptide (arginine-glycin-aspartic acid sequence), or mitomycin-C (MMC) is a pharmacological means of preventing or reducing the development of posterior capsule opacification (PCO).


METHODS
Department of Ophthalmology, Celal Bayar University, School of Medicine, Manisa, and Department of Pathology, Dokur Eylül University, School of Medicine, Izmir, Turkey.


METHODS
Fifty-four rabbits were randomly divided into 6 groups. Dexamethasone (4 mg/cc), diclofenac (2.5 mg/cc), EDTA (8 mg/cc), a combination of EDTA and RGD peptide (2.5 mg/cc), or MMC (0.04 mg/cc) was given, 0.1 cc by hydrodissection and 0.9 cc into the capsular bag after phacoemulsification. The sixth group served as a control group. After 3 months, the PCO was graded clinically and the proliferation of lens epithelial cells (LECs) was evaluated histologically.


RESULTS
The drugs were significantly effective in preventing PCO compared with the control (P <.005). Dexamethasone had a weaker effect than the other drugs. In histological analysis, although monolayer LECs in the dexamethasone and diclofenac groups were observed, there was no proliferative activity on the posterior capsules in the EDTA, EDTA+RGD, and MMC groups in contrast to the multilayer cells in the control.


CONCLUSIONS
Intraoperative single-dose application of EDTA, EDTA+RGD peptide combination, and MMC significantly prevented the development of PCO in rabbit eyes. Diclofenac was less effective but also reduced PCO. Although dexamethasone did not prevent the proliferation of LECs, it decreased PCO clinically.
Inan UU
Department of Ophthalmology, Afyon Kocatepe University, School of Medicine, 03200 Afyon, Turkey. uuinan@superonline.com
Oztürk
F
F
Kaynak
S
S
Kurt
E
E
Emiroğlu
L
L
Ozer
E
E
Ilker
S S
SS
Güler
C
C
D000818:Animals; D002386:Cataract / Q000473:pathology / Q000517:prevention & control*; D003907:Dexamethasone / Q000008:administration & dosage / Q000494:pharmacology*; D004008:Diclofenac / Q000008:administration & dosage / Q000494:pharmacology*; D004359:Drug Therapy, Combination; D004492:Edetic Acid / Q000008:administration & dosage / Q000494:pharmacology*; D004847:Epithelial Cells / Q000187:drug effects; D007903:Lens Capsule, Crystalline / Q000187:drug effects* / Q000473:pathology; D016685:Mitomycin / Q000008:administration & dosage / Q000494:pharmacology*; D009842:Oligopeptides / Q000008:administration & dosage / Q000494:pharmacology*; D018918:Phacoemulsification; D011817:Rabbits
D009842:Oligopeptides; D004008:Diclofenac; D016685:Mitomycin; C047981:arginyl-glycyl-aspartic acid; D003907:Dexamethasone; D004492:Edetic Acid